| scholarly article | Q13442814 |
| P2093 | author name string | Jonathan D Steckbeck | |
| Ronald C Desrosiers | |||
| Ronald C Montelaro | |||
| Kelly Stefano Cole | |||
| Jennifer L Rowles | |||
| P2860 | cites work | Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport | Q24633832 |
| Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding | Q24644617 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response | Q28282853 | ||
| Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells | Q28288205 | ||
| Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1 | Q28646731 | ||
| CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization | Q28646881 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections | Q33784692 | ||
| Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation | Q33814150 | ||
| N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism | Q33842455 | ||
| Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. | Q34349343 | ||
| Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response | Q34998032 | ||
| Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein | Q36549382 | ||
| Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity. | Q36634778 | ||
| Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. | Q36812220 | ||
| Sialic acids on the surface of caprine arthritis-encephalitis virus define the biological properties of the virus | Q36868748 | ||
| Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies | Q36884458 | ||
| Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins | Q38334915 | ||
| Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. | Q38359755 | ||
| Analysis of envelope changes acquired by SIVmac239 during neuroadaption in rhesus macaques | Q38874696 | ||
| Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus | Q38948757 | ||
| CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity | Q39370718 | ||
| Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine | Q39402713 | ||
| Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. | Q39581340 | ||
| Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein | Q39592994 | ||
| Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops | Q39602333 | ||
| CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. | Q39605077 | ||
| A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope | Q39682625 | ||
| Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity | Q39880154 | ||
| Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain | Q40746322 | ||
| Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. | Q40788362 | ||
| CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. | Q41151327 | ||
| Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines | Q41157521 | ||
| Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences | Q41436920 | ||
| Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. | Q41504258 | ||
| Complementation of human immunodeficiency virus glycoprotein mutations in trans | Q41609412 | ||
| Carbohydrate determinant NeuAc-Galbeta(1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120 | Q43446688 | ||
| An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization | Q43451743 | ||
| Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope | Q45733017 | ||
| V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. | Q45734123 | ||
| Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection | Q45756087 | ||
| Properties of virus-like particles produced by SIV-chronically infected human cell clones | Q45771901 | ||
| A role for carbohydrates in immune evasion in AIDS. | Q47982875 | ||
| N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization | Q56935643 | ||
| Hypothetical assignment of intrachain disulfide bonds for HIV-2 and SIV envelope glycoproteins | Q68029498 | ||
| Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual | Q73149263 | ||
| Maturation of envelope-specific antibody responses to linear determinants in monkeys inoculated with attenuated SIV | Q73208196 | ||
| A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys | Q73626426 | ||
| Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development | Q77550865 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glycosylation | Q898365 |
| Simian immunodeficiency virus | Q1890246 | ||
| P304 | page(s) | 1525-1539 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. | |
| P478 | volume | 78 |
| Q36149102 | A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. |
| Q37683178 | A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation |
| Q33522232 | A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein |
| Q34291727 | Algal lectins as potential HIV microbicide candidates |
| Q36747989 | An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies |
| Q36823297 | Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response |
| Q28751926 | Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys |
| Q35914280 | Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140 |
| Q36978861 | Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design |
| Q38877739 | DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. |
| Q35992786 | Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance |
| Q35666057 | Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins |
| Q34016211 | Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies |
| Q36802333 | Exploiting the defensive sugars of HIV-1 for drug and vaccine design |
| Q30397572 | Functional contributions of carbohydrate on AIDS virus glycoprotein |
| Q34120130 | Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages |
| Q38884170 | Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention |
| Q34555891 | Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity |
| Q36343536 | HIV vaccine design: insights from live attenuated SIV vaccines |
| Q83111898 | Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction |
| Q35101464 | Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity |
| Q37801269 | Human immunodeficiency virus-1 vaccine design: where do we go now? |
| Q35785244 | Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate |
| Q41838419 | In silico prediction of B cell epitopes of the extracellular domain of insulin-like growth factor-1 receptor |
| Q35955770 | Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation |
| Q37442592 | Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections |
| Q35635459 | Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines |
| Q35102328 | Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies |
| Q38860309 | Loss of a conserved N-linked glycosylation site in the simian immunodeficiency virus envelope glycoprotein V2 region enhances macrophage tropism by increasing CD4-independent cell-to-cell transmission |
| Q90270852 | MHC Class I Stability is Modulated by Cell Surface Sialylation in Human Dendritic Cells |
| Q45410457 | Mapping antigenic diversity and strain specificity of mumps virus: a bioinformatics approach |
| Q57091860 | Monitoring Viral Genetic Variation as a Tool To Improve Molecular Diagnostics for Mumps Virus |
| Q35857157 | Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques |
| Q39275435 | Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus |
| Q36806516 | Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection. |
| Q39723388 | Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization |
| Q39290859 | Sequential turnover of human immunodeficiency virus type 1 env throughout the course of infection |
| Q33385988 | Structural and thermodynamic approach to peptide immunogenicity |
| Q37314536 | Structure-based antigen design: a strategy for next generation vaccines |
| Q34005185 | Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy |
| Q34869463 | The multiple roles of sGP in Ebola pathogenesis |
| Q92478519 | V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers |
| Q34178201 | Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. |
| Q33883252 | posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate |
Search more.